

# ABIVAX S.A.

ISIN: FR0012333284 WKN: - Asset Class: **Stock**

## Company

2022/08/12 17:35:02



### Price

9.01 EUR

Difference ▲ 8.16%(0.68)



## Contact Details

ABIVAX SA Tel: 33-1-53-83-08-41  
-- Fax: -  
5, rue de la Baume Web: <http://www.abivax.com>  
75008 Paris E-mail: [info@abivax.com](mailto:info@abivax.com)

## Company Profile

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	74,713,000		36,544,000		17,092,000	
<b>Common stock capital</b>		168,000		143,000		122,000
<b>Fixed assets</b>	35,652,000		34,754,000		34,636,000	
<b>Equity capital of a company</b>		28,774,000		4,673,000		11,781,000
<b>Cash and cash equivalents</b>	60,695,000		29,296,000		9,765,000	
<b>Accrued liabilities</b>		98,000		1,000		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		31,521,000		24,944,000		15,749,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		50,070,000		41,681,000		24,198,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		6,837,000		13,235,000		6,816,000
<b>Total assets</b>	110,365,000	110,365,000	71,298,000	71,298,000	51,728,000	51,728,000

## Balance notes

	2021	2020	2019
<b>Accounting standard</b>	-	-	-
<b>Employees</b>	26	27	26
<b>Equity ratio</b>	26.07%	6.55%	22.77%
<b>Debt-equity ratio</b>	283.56%	1,425.74%	339.08%

## Others

	2021	2020	2019
<b>Tax Expense Rate</b>	9.23%	6.42%	12.20%

**Income statement**

	<b>2021</b>	<b>2020</b>	<b>2019</b>
<b>Turnover</b>	0	0	0
<b>Net income</b>	-41,357,000	-37,551,000	-30,634,000
<b>EBIT</b>	-42,435,000	-37,808,000	-33,259,000
<b>Operating income before taxes</b>	-45,561,000	-40,126,000	-34,891,000
<b>Cash Flow</b>	-45,657,000	-29,823,000	-27,473,000
<b>Net interest income</b>	-3,126,000	-2,318,000	-1,632,000
<b>Research and development expenses</b>	47,202,000	34,526,000	29,007,000
<b>Income taxes</b>	-4,204,000	-2,575,000	-4,257,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	0	0	0

**Board of Directors**

Philippe Pouletty	Chairman of Supervisory Board
Antonino Ligresti	Member of Supervisory Board
Carol Brosgart	Member of Supervisory Board
Christian Pierret	Member of Supervisory Board
Kinam Hong	Member of Supervisory Board
Corinna Zur Bonsen-Thomas	Member of Supervisory Board
Jean-Jacques Bertrand	Member of Supervisory Board
Joy Amundson	Member of Supervisory Board

**Members of Management Board**